ClinicalTrials.gg
Active, not recruitingNCT04446117CONTACT-02Updated Dec 18, 2025Results posted

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

A Phase 3 interventional study of Cabozantinib and Atezolizumab in Metastatic Prostate Cancer and Prostate Adenocarcinoma, sponsored by Exelixis. Active, not recruiting at 280 sites in 27 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
575
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing cabozantinib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 2 of them phase 3. cabozantinib · Prostatic Neoplasms.

Enrollment
4th of 23
575 · median 33
Started
2020
with 1 other
Phase 3
4 of 23
1 open now
Registered
16th of 23
by date
Lead sponsor
6 of 23
Exelixis

Among the 23 studies testing cabozantinib in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 3, and was the 16th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 23 studies testing cabozantinib in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cabozantinib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.

Read the detailed description

The primary objective of this study is to evaluate the efficacy of cabozantinib (XL184) in combination with atezolizumab versus a second NHT (abiraterone or enzalutamide) in subjects with mCRPC who have previously been treated with one, and only one, NHT (e.g. abiraterone, apalutamide, darolutamide, or enzalutamide) to treat metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic CRPC (M0 CRPC), or mCRPC, and who have measurable extrapelvic disease. The multiple primary efficacy endpoints comparing the experimental arm and control arm are Duration of Progression Free Survival (PFS) per RECIST 1.1 by Blinded Independent Radiology Committee (BIRC) and Duration of Overall Survival (OS). The secondary efficacy endpoint is Objective Response Rate (ORR) per RECIST 1.1 per BIRC.

03

Conditions studied

  • Metastatic Prostate Cancer
  • Prostate Adenocarcinoma

Browse trials for

Keywords

  • prostate cancer
  • castration-resistant prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men with or cytologically confirmed adenocarcinoma of the prostate
  • Prior treatment with one, and only one, NHT (eg, abiraterone, apalutamide, darolutamide, or enzalutamide) for castration-sensitive locally advanced (T3 or T4) or mCSPC, M0 CRPC, or mCRPC
  • Surgical or medical castration, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening
  • Measurable (extrapelvic soft tissue) disease per Investigator assessment defined by at least one of the following: measurable visceral disease (eg, adrenal, kidney, liver, lung, pancreas, spleen) per 1.1; OR measurable extrapelvic adenopathy (ie, adenopathy above the aortic bifurcation)
  • Progressive disease at study entry as defined by specific criteria for prostate specific antigen (PSA) progression OR soft tissue disease progression in the opinion of the Investigator (Note: subjects with bone disease progression alone are not eligible)
  • Age ≥ 18 years old or meeting country definition of adult, whichever is older, on the day of consent
  • performance status of 0 or 1
  • Recovery to baseline or ≤ Grade 1 per (CTCAE) v5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy in the opinion of the Investigator
  • Adequate organ and marrow function based upon specific laboratory assessments obtained within 21 days prior to randomization
  • Understanding and ability to comply with protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Any prior nonhormonal therapy initiated for the treatment of mCRPC
  • Receipt of abiraterone within 1 week; cyproterone within 10 days; or flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen-receptor inhibitors within 2 weeks before randomization
  • Radiation therapy within 4 weeks (2 weeks for bone ) prior to randomization (subjects with ongoing complications from prior radiation therapy are not eligible)
  • Known or cranial epidural disease unless adequately treated and clinically stable at least 4 weeks prior to randomization
  • Symptomatic or impending spinal cord compression or cauda equina syndrome
  • Concomitant anticoagulation with oral anticoagulants (some specific exceptions apply)
  • Administration of a live, attenuated vaccine within 30 days prior to randomization
  • Systematic treatment with, or any condition requiring, either (>10 mg daily prednisone equivalent) or other medications within 14 days prior to randomization
  • Uncontrolled, significant intercurrent or recent illness
  • Major surgery within 4 weeks prior to randomization
  • interval calculated by the Fridericia formula (QTcF) > 480 ms per within 21 days before randomization
  • Inability or unwillingness to swallow pills or receive IV administration
  • Previously identified allergy or to components of the study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies
  • Any other active at time of randomization or diagnosis of another malignancy within 2 years prior to randomization that requires active treatment (some exceptions apply such as locally curable cancers that have apparently been cured).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
575 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w

    Drug: Cabozantinib · Drug: Atezolizumab

  • Active comparator
    Control Arm

    Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization

    Drug: Abiraterone Acetate · Drug: Enzalutamide · Drug: Prednisone

Interventions

  • Supplied as 20-mg tablets; administered orally daily at 40mg

    Also known as: XL184, Cabometyx®

  • Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)

    Also known as: Tecentriq®

  • Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid

    Also known as: Abiraterone, Zytiga

  • Supplied as 40 mg capsules; administered orally daily at 160mg

    Also known as: Xtandi

  • Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily

06

What researchers measure

Primary outcomes

  1. Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)

    Duration of PFS was defined as the time from randomization to the earlier of either the date of radiographic progression (defined as progressive disease \[PD\] per RECIST 1.1) per BIRC or the date of death due to any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with an absolute increase of ≥ 5 mm, unequivocal progression of non-target lesions and/or the appearance of new lesions.

    Time frame: Up to a maximum of approximately 30 months (Median duration of follow-up was 14.31 months)

  2. Duration of Overall Survival (OS)

    Duration of OS was defined as the time from randomization to death due to any cause. For participants, who were not known to have died at the time of data cutoff and were permanently lost to follow-up, duration of OS was censored at the earlier of the following dates: date the participant was last known to be alive or date of full withdrawal of consent (including survival follow-up), or date of data cutoff. OS was calculated as earlier of date of death or censoring - date of randomization + 1)/30.4375

    Time frame: Up to a maximum of approximately 45 months (Median duration of follow-up was 24.05 months)

07

Results

Posted Dec 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneExperimental Arm: Cabozantinib and AtezolizumabControl Arm: Second Novel Hormonal Therapy (NHT)
Started289286
Received at least 1 dose of any study treatment284284
Received cabozantinib or atezolizumab2840
Received abiraterone and prednisone or enzalutamide1283
Discontinued radiographic follow-up267265
Discontinued survival follow-up202202
Completed2220
Not completed267266
Withdrew: No study treatment given43
Withdrew: Radiographic disease progression132158
Withdrew: Adverse event7943
Withdrew: Lack of clinical benefit11
Withdrew: Withdrawal by subject2422
Withdrew: Lost to follow-up03
Withdrew: Miscellaneous2636
Withdrew: Missing data/data not yet received10

Outcome measures

PrimaryDuration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)

Duration of PFS was defined as the time from randomization to the earlier of either the date of radiographic progression (defined as progressive disease \[PD\] per RECIST 1.1) per BIRC or the date of death due to any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with an absolute increase of ≥ 5 mm, unequivocal progression of non-target lesions and/or the appearance of new lesions.

Time frame:
Up to a maximum of approximately 30 months (Median duration of follow-up was 14.31 months)
Reported as:
Median · months
Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)
monthsExperimental Arm: Cabozantinib and AtezolizumabControl Arm: Second NHT
Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)6.34 (6.18 to 8.80)4.17 (3.71 to 5.65)
Statistical analysis
  • Experimental Arm: Cabozantinib and Atezolizumab vs Control Arm: Second NHT · Log Rank · p = 0.0007 (Stratification factors used: Liver metastasis, prior docetaxel use for locally advanced or metastatic castration-sensitive prostate cancer (mCSPC) and disease state at first NHT.) · Cox proportional hazard: 0.65 · 95% CI 0.50 to 0.84Stratification factors used: Liver metastasis, prior docetaxel use for locally advanced or mCSPC and disease state at first NHT.
PrimaryDuration of Overall Survival (OS)

Duration of OS was defined as the time from randomization to death due to any cause. For participants, who were not known to have died at the time of data cutoff and were permanently lost to follow-up, duration of OS was censored at the earlier of the following dates: date the participant was last known to be alive or date of full withdrawal of consent (including survival follow-up), or date of data cutoff. OS was calculated as earlier of date of death or censoring - date of randomization + 1)/30.4375

Time frame:
Up to a maximum of approximately 45 months (Median duration of follow-up was 24.05 months)
Reported as:
Median · months
Duration of Overall Survival (OS)
monthsExperimental Arm: Cabozantinib and AtezolizumabControl Arm: Second NHT
Duration of Overall Survival (OS)14.78 (13.37 to 16.66)14.98 (13.01 to 18.50)
Statistical analysis
  • Experimental Arm: Cabozantinib and Atezolizumab vs Control Arm: Second NHT · Log Rank · p = 0.2956 (Stratification factors used: Liver metastasis, prior docetaxel use for locally advanced or mCSPC and disease state at first NHT.) · Cox proportional hazard: 0.89 · 95% CI 0.72 to 1.10

Adverse events

Collected over Up to a maximum of approximately 45 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Arm: Cabozantinib and Atezolizumab173/284 (60.9%)135/284 (47.5%)281/284 (98.9%)
Control Arm: Second NHT179/284 (63%)89/284 (31.3%)254/284 (89.4%)
Most frequent serious events
Showing 10 of 170
Most frequent serious events
EventExperimental Arm: Cabozantinib and AtezolizumabControl Arm: Second NHT
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)22/28420/284
Pulmonary embolismRespiratory, thoracic and mediastinal disorders10/2841/284
Acute kidney injuryRenal and urinary disorders9/2843/284
PneumoniaInfections and infestations8/2842/284
Urinary retentionRenal and urinary disorders8/2841/284
AnaemiaBlood and lymphatic system disorders5/2848/284
Urinary tract infectionInfections and infestations7/2844/284
DiarrhoeaGastrointestinal disorders7/2840/284
General physical health deteriorationGeneral disorders3/2846/284
VomitingGastrointestinal disorders5/2843/284
Most frequent other events
Showing 10 of 50
Most frequent other events
EventExperimental Arm: Cabozantinib and AtezolizumabControl Arm: Second NHT
DiarrhoeaGastrointestinal disorders133/28419/284
Decreased appetiteMetabolism and nutrition disorders113/28443/284
FatigueGeneral disorders85/28457/284
NauseaGastrointestinal disorders80/28436/284
AstheniaGeneral disorders77/28437/284
AnaemiaBlood and lymphatic system disorders77/28452/284
Aspartate aminotransferase increasedInvestigations70/28415/284
Alanine aminotransferase increasedInvestigations69/2849/284
HypothyroidismEndocrine disorders65/2844/284
HypertensionVascular disorders60/28420/284

Baseline characteristics

Intent-to-treat (ITT) population: Included all participants who were randomized regardless of whether any study treatment or the correct study treatment was received.

Age, Categorical
Age, Categorical(Participants)Experimental Arm: Cabozantinib and AtezolizumabControl Arm: Second NHTTotal
<=18 years000
Between 18 and 65 years5467121
>=65 years235219454
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Arm: Cabozantinib and AtezolizumabControl Arm: Second NHTTotal
Female000
Male289286575
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental Arm: Cabozantinib and AtezolizumabControl Arm: Second NHTTotal
Hispanic or Latino7772149
Not Hispanic or Latino196196392
Unknown or Not Reported161834
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Experimental Arm: Cabozantinib and AtezolizumabControl Arm: Second NHTTotal
American Indian/Alaska Native3912
Asian393978
Black/African American099
Native Hawaiian/Pacific Islander101
White227213440
Multiple101
Other235
Not Reported161329
08

Study locations

280 sites
  • Exelixis Clinical Site #4
    Tucson, Arizona 85741, United States
  • Exelixis Clinical Site #42
    Duarte, California 91010, United States
  • Exelixis Clinical Site #2
    Fullerton, California 92835, United States
  • Exelixis Clinical Site #224
    La Jolla, California 92093-0698, United States
  • Exelixis Clinical Site #3
    Marina del Rey, California 90292, United States
  • Exelixis Clinical Site #114
    San Diego, California 92161, United States
  • Exelixis Clinical Site #125
    Santa Monica, California 90404, United States
  • Exelixis Clinical Site #245
    Stanford, California 94305, United States
  • Exelixis Clinical Site #91
    Aurora, Colorado 80045, United States
  • Exelixis Clinical Site #14
    Denver, Colorado 80211, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Yale University, School of Medicine
    New Haven, Connecticut 06520, United States
  • Exelixis Clinical Site #108
    Miami, Florida 33125, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Exelixis Clinical Site #215
    Westwood, Kansas 66205, United States
  • Exelixis Clinical Site #242
    Louisville, Kentucky 40202, United States
  • Exelixis Clinical Site #6
    Baltimore, Maryland 21204, United States
  • Non-participating Site
    Detroit, Michigan 48202, United States
  • Exelixis Clinical Site #203
    Rochester, Minnesota 55905, United States
  • Exelixis Clinical Site #19
    Omaha, Nebraska 68130, United States
  • Exelixis Clinical Site #144
    Las Vegas, Nevada 89169, United States
  • Exelixis Clinical Site #123
    East Brunswick, New Jersey 08816, United States
  • Non-participating Site
    Lawrenceville, New Jersey 08648, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Exelixis Clinical Site #198
    The Bronx, New York 10461, United States
  • Exelixis Site #159
    Cleveland, Ohio 44195, United States
  • Exelixis Clinical Site #221
    Oklahoma City, Oklahoma 73104, United States
  • Exelixis Clinical Site #18
    Philadelphia, Pennsylvania 19111, United States
  • Exelixis Clinical Site #201
    Pittsburgh, Pennsylvania 15232, United States
  • Exelixis Clinical Site #1
    Nashville, Tennessee 37209, United States
  • Exelixis Clinical Site #5
    Houston, Texas 77027, United States
  • Exelixis Clinical Site #177
    Houston, Texas 77030, United States
  • Exelixis Clinical Site #259
    Houston, Texas 77030, United States
  • Exelixis Clinical Site #41
    Temple, Texas 76504, United States
  • Exelixis Clinical Site #67
    Salt Lake City, Utah 84112, United States
  • Exelixis Clinical Site #143
    Roanoke, Virginia 24014, United States
  • Exelixis Clinical Site #122
    Ciudad Autonoma de Buenos Aire, Buenos Aires C1280AEB, Argentina
  • Exelixis Clinical Site #120
    Mar del Plata, Buenos Aires B7600FZO, Argentina
  • Exelixis Site #170
    Pergamino, Buenos Aires B2700CPM, Argentina
  • Exelixis Clinical Site #210
    Córdoba, Córdoba Province X5004FHP, Argentina
  • Exelixis Clinical Site #152
    Viedma, Río Negro Province R8500ACE, Argentina
  • Exelixis Clinical Site #183
    Rosario, Santa Fe Province S2000CVB, Argentina
  • Exelixis Clinical #261
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Exelixis Clinical Site #200
    Buenos Aires, C1426ANZ, Argentina
  • Exelixis Clinical Site #256
    Caba, C1120AAT, Argentina
  • Exelixis Clinical Site #44
    Ciudad Autonoma de Buenos Aire, C1012AAR, Argentina
  • Exelixis Clinical Site #105
    La Rioja, F5300, Argentina
  • Exelixis Clinical Site #124
    San Juan, 5400, Argentina
  • Exelixis Clinical Site #101
    San Salvador de Jujuy, Y4600EHA, Argentina
  • Exelixis Clinical Site #151
    Garran, Australian Capital Territory 2605, Australia
  • Exelixis Clinical Site #252
    Port Macquarie, New South Wales 2444, Australia
  • Exelixis Clinical Site #175
    Saint Leonards, New South Wales 2065, Australia
  • Exelixis Clinical Site # 189
    Sydney, New South Wales 2109, Australia
  • Exelixis Site #162
    Wollongong, New South Wales 2500, Australia
  • Exelixis Clinical Site #253
    Chermside, Queensland 4032, Australia
  • Exelixis Clinical Site #103
    Launceston, Tasmania 7250, Australia
  • Exelixis Clinical Site #79
    Ballarat, Victoria 3350, Australia
  • Exelixis Clinical Site #95
    Frankston, Victoria 3199, Australia
  • Exelixis Clinical #262
    Geelong, Victoria 3220, Australia
  • Exelixis Clinical Site #53
    Melbourne, Victoria 3000, Australia
  • Exelixis Clinical Stie #260
    Saint Albans, Victoria 3021, Australia
  • Exelixis Clinical Site #115
    Adelaide, 5000, Australia
  • Exelixis Clinical Site #149
    Box Hill, 3128, Australia
  • Exelixis Clinical Site #156
    Linz, Upper Austria 4020, Austria
  • Exelixis Site #158
    Linz, Upper Austria 4020, Austria
  • Exelixis Clinical Site #218
    Vienna, 1080, Austria
  • Exelixis Clinical Site #126
    Bonheiden, Antwerpen 2820, Belgium
  • Exelixis Clinical Site #39
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Exelixis Clinical Site #141
    Brussels, 1000, Belgium
  • Exelixis Site #165
    Roeselare, 8800, Belgium
  • Exelixis Site #163
    Curitiba, Paraná 80510-130, Brazil
  • Exelixis Clinical Site #204
    Curitiba, Paraná 80520-174, Brazil
  • Exelixis Clinical Site #171
    Rio de Janeiro, Rio de Janeiro 22793-080, Brazil
  • Exelixis Site #157
    Porto Alegre, Rio Grande do Sul 90610-00, Brazil
  • Exelixis Clinical Site #132
    Blumenau, Santa Catarina 89010-340, Brazil
  • Exelixis Clinical Site #191
    Campinas, São Paulo 13083-970, Brazil
  • Exelixis Clinical Site #128
    Ribeirão Preto, São Paulo 14048-900, Brazil
  • Exelixis Clinical Site #106
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Exelixis Site #161
    São Paulo, São Paulo 04538-132, Brazil
  • Exelixis Clinical Site #154
    Barretos, 14784-400, Brazil
  • Exelixis Clinical Site #140
    Fortaleza, 60336-232, Brazil
  • Exelixis Clinical Site #153
    Porto Alegre, 90110-270, Brazil
  • Exelixis Clinical Site #145
    Ribeirão Preto, 14015-130, Brazil
  • Exelixis Clinical Site #116
    Santa Cruz do Sul, 96810-110, Brazil
  • Exelixis Clinical Site #69
    Edmonton, Alberta T6G 1Z2, Canada
  • Exelixis Clinical Site #112
    Kelowna, British Columbia V1Y 5L3, Canada
  • Exelixis Clinical Site #147
    Moncton, New Brunswick E1C 6Z8, Canada
  • Exelixis Clinical Site #83
    Hamilton, Ontario L8V 5C2, Canada
  • Exelixis Clinical Site #127
    London, Ontario N6A 5W9, Canada
  • Exelixis Clinical Site #7
    Oakville, Ontario L6H 3PI, Canada
  • Exelixis Clinical Site #178
    Granby, Quebec J2GIT7, Canada
  • Exelixis Site #160
    Montreal, Quebec H2X 3E4, Canada
  • Exelixis Clinical #263
    Santiago, Santiago Metropolitan 7500787, Chile
  • Exelixis Clinical Site #139
    Santiago, Santiago Metropolitan 7500921, Chile
  • Exelixis Clinical Site #247
    Viña del Mar, Valparaiso 2520598, Chile
  • Exelixis Clinical Site #142
    Providencia, 7500713, Chile
  • Exelixis Clinical Site #148
    Recoleta, 8420383, Chile
  • Exelixis Clinical Site #90
    Santiago, 7500653, Chile
  • Exelixis Clinical Site #113
    Temuco, 4810469, Chile
  • Exelixis Clinical Site #119
    Valparaíso, 2540333, Chile

Showing the first 100 of 280 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Agarwal N, Azad AA, Carles J, Matsubara N, Oudard S, Saad F, Merseburger AS, Soares A, McGregor BA, Zurawski B, Tsiatas M, North S, Bondarenko I, Alfie M, Bournakis E, Antonuzzo L, Evilevitch L, Simmons A, Wang F, Ferraldeschi R, Nandoskar P, Pal SK. Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. Lancet Oncol. 2025 Jul;26(7):860-876. doi: 10.1016/S1470-2045(25)00209-8. Epub 2025 Jun 13. PubMed 40523369 ↗
  • Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar;18(10):1185-1198. doi: 10.2217/fon-2021-1096. Epub 2022 Jan 17. PubMed 35034502 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Apr 2024, 42 months.

Results were first posted in Dec 2025, 1 year 7 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 42 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2020
First posted
Jun 24, 2020
StartActual
Oct 19, 2020
Primary completionActual
Apr 19, 2024
CompletionEst.
Oct 16, 2026
Results first posted
Dec 18, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04446117
Lead sponsor
Exelixis
Collaborators
Roche-Genentech, Takeda
Responsible party
Sponsor
First posted
Jun 24, 2020
Start date
Oct 19, 2020
Primary completion
Apr 19, 2024
Completion
Oct 16, 2026 (estimated)
Results posted
Dec 18, 2025
Last update
Dec 18, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabozantinib · Atezolizumab

Start the discussion